Optimal oversizing in transcatheter aortic valve replacement with the self-expanding Evolut valve system.

TAVR aortic valve stenosis oversizing paravalvular leak self-expandable transcatheter aortic valve replacement

Journal

The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477

Informations de publication

Date de publication:
04 Mar 2024
Historique:
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

Valve oversizing has been associated with reduced paravalvular leaks (PVL) and valve migration risk. However, no optimal cut-off oversizing value has been defined for the Evolut system (Medtronic). The aim of this study was to assess the relationship between the degree of oversizing and moderate-to-severe PVL and determine the optimal oversizing cut-off value. We conducted a multicenter study that included 740 consecutive patients with multidetector computed tomography (CT) data. Valve size was selected according to manufacturer recommendations, with oversizing ranging from 10% to 30%. The primary endpoint was moderate-to-severe PVL. The median age was 84 years (79-87 years), with 58.4% women, and a median EuroSCORE II of 4.1% (2.4-7.3%). Moderate-to-severe PVL was observed in 7.0% of the patients. An inverse relationship was found between oversizing and both PVL (11.3%, 8.6%, 5.4%, and 2.7% for quartiles Q1 to Q4; P = .007) and the need for post-dilation (P = .016). The multivariable analysis showed an association between oversizing and PVL (OR: 0.915 for each 1%-increase, P = .002). The optimal oversizing cut-off value to predict PVL was 20%, and PVL was significantly higher in patients with oversizing less than 20% (10.5% vs.4.2%, P less than .001). There were no differences in major clinical events according to the degree of oversizing, and a higher oversizing did not translate into an increased risk of permanent pacemaker (18.4% vs18.3%, P = .976). In TAVR with the Evolut valve, a higher oversizing was associated with lower rates of moderate-to-severe PVL and a lower need for post-dilation, with no negative impact on procedural and early clinical outcomes. A 20% oversizing threshold could be suggested to reduce PVLs. Further prospective studies are warranted to validate optimal oversizing for this valve system.

Identifiants

pubmed: 38446025
doi: 10.25270/jic/24.00011
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Silvia Mas-Peiro (S)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Alberto Alperi (A)

Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Marisa Avvedimento (M)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Ander Regueiro (A)

Cardiology Department, Instituto Clínic Cardiovascular, Hospital Clínic, Barcelona, Spain and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Pablo Avanzas (P)

Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Domenico Angellotti (D)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Giovanni Esposito (G)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Pablo Vidal-Cales (P)

Cardiology Department, Instituto Clínic Cardiovascular, Hospital Clínic, Barcelona, Spain and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Siamak Mohammadi (S)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Julio Farjat (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Cesar Moris (C)

Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Cardiology Department, Instituto Clínic Cardiovascular, Hospital Clínic, Barcelona, Spain and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. E-mail: josep.rodes@criucpq.ulaval.ca.

Classifications MeSH